To include your compound in the COVID-19 Resource Center, submit it here.

Getting hip in osteoporosis

Why romosozumab needs hip data to compete in osteoporosis

Investors were quick to conclude that Amgen Inc. and UCB Group's romosozumab may be at a disadvantage in the osteoporosis market after the partners reported a miss on non-vertebral fracture rates, and an apparently lower reduction in vertebral fracture rates than Radius Health Inc. has reported for abaloparatide-SC.

But doctors who spoke to BioCentury said if detailed data show evidence of efficacy on hip fractures, the mAb's monthly dosing schedule could level the playing field because of concerns that patients may not comply with abaloparatide-SC's once-daily regimen.

Romosozumab stimulates bone growth by targeting sclerostin, a protein secreted by osteocytes that inhibits bone formation. Abaloparatide-SC is a subcutaneous peptide analog of parathyroid hormone-related protein (PTHrP) that also stimulates bone growth.

The compounds would complement drugs that block bone resorption, such as oral bisphosphonates and Amgen's Prolia denosumab. They would complete with Eli Lilly and Co.'s Forteo teriparatide, a recombinant parathyroid hormone (PTH 1-34) that is the only approved osteoporosis agent that stimulates new bone

Read the full 1649 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE